Skip to content

Anti-cold prescription in the treatment of common cold (Fengre syndrome)

Anti-cold prescription in the treatment of common cold (Fengre syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001564
Enrollment
Unknown
Registered
2011-09-22
Start date
2011-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common cold (Fengre Syndrome)

Interventions

1:Anti-cold Prescription decoction
2:Placebo-controlled decoction

Sponsors

China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic standard of cold; 2) Meet the Fengre syndrome of TCM standards; 3) body temperature between 37.5 to 39.0 degree C; 4) TCM symptom total score >=8 points; 5) between the ages of 18 to 45 yesrs old; 6) within 48h after the onset of common cold; 7) According to the GCP requirement for informed consent, voluntary subjects.

Exclusion criteria

Exclusion criteria: 1. WBC count> 11*10^9/L or neutrophils> 80%; 2. pregnant women or lactating women; 3. associated with allergic rhinitis, throat - conjunctivitis, herpes angina, bronchitis, pneumonia, tonsillitis and other diseases; 4. The accepted after the onset of other anti-virus, anti-inflammatory, anti-inflammatory drugs or any other flu treatment drugs; 5. associated with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system of primary and other serious diseases; 6. liver and kidney dysfunction: liver function (ALT or AST) or more than double the upper limit of normal renal function (BUN or Cr) abnormalities; 7.mental illness; 8. allergies and allergic to the drug; 9. has a history of drug abuse; 10. a month who have participated in other clinical trials; 11. Researchers believe that is not suitable for selected other conditions.

Design outcomes

Primary

MeasureTime frame
Determine the efficacy of diseas;

Secondary

MeasureTime frame
Onset time, antipyretic time, the efficacy of individual symptoms and signs;

Countries

China

Contacts

Public ContactYan Lei
leiy999@163.com+86 010-64014411-2411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026